NASDAQ
18.15USD
-0.53 (-2.84%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
6.3B
P/E
—
EPS
—
Beta
0.67
52W range
1.33-24.28
Day range
17.77–18.92
Open
18.86
Prev close
18.68
Volume
2.6M
Avg volume
5.4M
Dividend
0.00
IPO
2021-07-16
https://www.newsfilecorp.com/release/307456/ERAS-SHAREHOLDER-NOTICE-Faruqi-Faruqi-LLP-Reminds-Erasca-ERAS-Investors-of-Securities-Class-Action-Lawsuit-Deadline-on-August-10-2026 · 8/2/2026-1.00
https://www.newsfilecorp.com/release/306860/ADMA-BIOLOGICS-INC.-ADMA-INVESTOR-ALERT-Berger-Montague-Advises-Investors-to-Inquire-About-a-Securities-Fraud-Class-Action · 7/29/2026-0.80
https://www.newsfilecorp.com/release/306151/ERAS-INVESTOR-DEADLINE-APPROACHING-Faruqi-Faruqi-LLP-Reminds-Erasca-ERAS-Investors-of-Securities-Class-Action-Lawsuit-Deadline-on-August-10-2026 · 7/24/2026-1.00
https://www.newsfilecorp.com/release/305563/ERAS-CLASS-ACTION-NOTICE-Faruqi-Faruqi-LLP-Reminds-Erasca-ERAS-Investors-of-Securities-Class-Action-Lawsuit-Deadline-on-August-10-2026 · 7/20/2026
https://www.prnewswire.com/news-releases/eras-investor-deadline-erasca-inc-investors-with-substantial-losses-have-opportunity-to-lead-investor-class-action-lawsuit--hbss-302825729.html · 7/15/2026-1.00
https://www.prnewswire.com/news-releases/investor-deadline-verra-mobility-corp-vrrm-investors-with-substantial-losses-have-opportunity-to-lead-the-verra-mobility-class-action-lawsuit-hbss-302825724.html · 7/15/2026-1.00
https://www.prnewswire.com/news-releases/erasca-eras-faces-securities-class-action-after-stock-declines-48-on-drug-safety-and-ip-concerns---hbss-302820077.html · 7/8/2026-1.00
https://www.globenewswire.com/news-release/2026/07/06/3322768/32716/en/Erasca-ERAS-Faces-Securities-Class-Action-After-Stock-Declines-48-on-Drug-Safety-and-IP-Concerns-HBSS.html · 7/6/2026-1.00
https://www.globenewswire.com/news-release/2026/07/03/3321965/32716/en/Erasca-Inc-ERAS-Faces-Securities-Class-Action-Amid-Patient-Death-Intellectual-Property-Questions-2-8-Billion-Market-Cap-Loss-HBSS.html · 7/3/2026-1.00
https://www.prnewswire.com/news-releases/erasca-inc-eras-faces-securities-class-action-amid-patient-death-intellectual-property-questions-2-8-billion-market-cap-loss----hbss-302813490.html · 6/29/2026-1.00
https://www.globenewswire.com/news-release/2026/06/22/3315575/32716/en/Sportradar-Group-AG-SRAD-Facing-Securities-Class-Action-Amid-Activist-Short-Seller-Accusations-of-Illegal-Business-Model-and-800-Million-Market-Cap-Wipeout-Hagens-Berman.html · 6/22/2026-0.60
https://www.globenewswire.com/news-release/2026/06/22/3315573/32716/en/Hagens-Berman-Alerts-Veritone-Inc-VERI-Investors-to-Securities-Class-Action-After-Admitted-Improper-Revenue-Accounting.html · 6/22/2026-1.00
Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the RAS/MAPK pathway. The firm's pipeline features several key experimental drugs: ERAS-007, an orally administered ERK1/2 inhibitor designed to address non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor targeting patients with advanced or metastatic solid tumors. Additionally, Erasca is progressing ERAS-801, an EGFR inhibitor capable of penetrating the central nervous system, intended for recurrent glioblastoma multiforme. The company was founded in 2018 and maintains its headquarters in San Diego, California.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
